Corporate Banner
Satellite Banner
Technology Networks Header
Friday, December 19, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients with Acute Leukemia
This study describes a new marker that might help doctors choose the least toxic, most effective treatment for older patients with acute myeloid leukemia.
Proteins Drive Cancer Cells To Change States
When RNA-binding proteins are turned on, cancer cells get locked in a proliferative state.
Signaling Mechanism Could Be Target For Survival, Growth Of Tumor Cells In Brain Cancer
Non-canonical EGFR signalling shown to make glioblastoma tumor cells more resistant to chemotherapy treatment.
New Way To Turn Genes On
Technique allows rapid, large-scale studies of gene function.
CSHL Team Finds a Way to Make shRNA Gene Knockdown More Effective
A powerful algorithm that improves the effectiveness of an important research technology.
Genes that Cause Pancreatic Cancer Identified by New Tool
Screening system in mice spots cancerous changes invisible to sequencing.
A Yardstick to Measure the Malignancy of Prostate Cancer
Researchers have been searching for regulatory proteins that change the epigenetic characteristics of prostate cancer cells.
Genetic Errors Linked To Aging Underlie Leukemia That Develops After Cancer Treatment
New research by Daniel Link, MD, and colleagues at The Genome Institute at Washington University has revealed that mutations that accumulate randomly as a person ages can play a role in a fatal form of leukemia that develops after treatment for another cancer.
New Cause of Child Brain Tumour Condition Identified
Doctors and scientists have identified changes in SUFU gene which can cause Gorlin syndrome.
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Scroll Up
Scroll Down
Return
Non Viral Reagent for Efficient siRNA Delivery
Anne-Laure Bolcato-Bellemin, In vivo Research Manager, Polyplus-transfection, speaking at RNAi World Congress 2009
Date Posted: Monday, November 02, 2009
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Polyplus-transfection Licenses Roche Glycart AG for PEI in vitro Transfection Applications for Research Purposes
Polyplus-transfection SA, a privately-held company developing innovative solutions for the delivery of nucleic acids in research, bioproduction and therapy, announced today that it has granted Roche Glycart AG, a Swiss biotechnology company fully-owned by Roche, a non exclusive license to use polyethylenimine (PEI) for in vitro transfection applications for research purposes.
Monday, January 24, 2011
Genethon to Use Polyplus-transfection’s jetPEI™ Transfection Reagent for Producing Viral Vectors
Genethon will use the jetPEI transfection reagent in the process of developing gene therapies for the treatment of rare diseases.
Friday, September 10, 2010
Polyplus-transfection Raises EUR 1.2 Million through an Issue of Convertible Bonds
New money will fund the company’s RNAplus research program and strengthen its human and material resources.
Friday, December 11, 2009
Polyplus-transfection Unveils Technology to Improve Intracellular Delivery of Small Interfering RNAs In-vivo
The "Sticky siRNA" technology is already being tested in vivo by academic laboratories and biotech companies.
Friday, April 25, 2008
 
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn